|
|
Caliper Life Sciences (CALP)This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below. From 1Table of contents
Company Information:Company Address: 68 Elm Street Hopkinton, MA 01748
Company’s Web Address: http://www.caliperls.com/
Industry Sector:
Fiscal Year: Dividend:
Note: this section is not editable.
Please click here to report any inaccuracies.
Company Overview:Note: this section is not editable.
Based in Hopkinton, MA, Caliper Life Sciences, Inc. (CALP) develops and commercializes life science instruments and related consumables and services for use in drug discovery and development and other life sciences research. Caliper makes specialized LabChips (roughly one-inch in diameter) that miniaturize, integrate, and automate laboratory functions, with the intention of enhancing the capabilities, and reducing the size of laboratories. Microfluidic chips, experiment-specific reagents, and related software are the main constituents of these specialized systems. The chips consist of a network of miniaturized, microfabricated channels through which chemicals and other fluids can be transported. After introducing reagents (chemical agents, dyes, or other materials required for biological experiments) automatically or by the user depending on the chip format, the instrument and specialized software (for scheduling, integration, and data management) after placement of the chip move the fluids in the network with pressure or electricity. Additionally, Caliper's high and ultra-high throughput screening systems, liquid handlers, advanced robotics (for automation), storage devices, and workstations (for dissolution, extraction, and evaporation) offer complete solutions to the pharmaceutical, biotechnology, chemical, agriculture, and food industries. The company s systems improve research efficiency by providing more accurate data at lower costs and higher speeds. The acquisition of NovaScreen in October 2005 expanded Caliper s service offerings. The acquisition of Xenogen in August 2006 expanded the company into the molecular imaging market. With Xenogen s imaging technologies, Caliper is able to provide an integrated package of products and services for both in vitro and in vivo research in drug discovery. In 2007, product revenue, service revenue (product support, validation services, drug discovery & development services, screening & profiling services, assay development services, & contract research & transgenic animal services), and license fees and contract revenue (from collaborations) contributed 59%, 27%, and 14%, respectively, to total revenue.
Valuation:Enter Valuation Analysis and Valuation Ratios Here
Projected Financials:Income Statement: (Paste Here) Balance Sheet: (Paste Here) Cash Flow Statement: (Paste Here) Financial Ratios: (Paste Here) Other: (Paste Here) News:
Tags:
none
The opinions and views expressed in this document do not necessarily reflect the views or opinions of InvestingMinds. InvestingMinds did not prepare and does not endorse such content. Please note that it is intended for general circulation only and the recommendations contained herein do not take into account the specific investment objectives, financial situation or particular needs of any particular person. This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy securities or other instruments. No part of this document may be reproduced in any manner without the written permission of InvestingMinds.
|
||||||||||||||||||||||||||||||
|
|